Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

30

Revenue 2017

Botox/Neuromodulator

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Botox/Neuromodulator was produced by Allergan.

Kythera bags FDA approval for double chin therapy

Kythera bags FDA approval for double chin therapy injected under the chin and is tipped by some market observers as being the next Botox. ... Earlier this month the FDA warned of yet another incident in which counterfeit Botox may have found its way into doctors' offices and medical clinics nationwide.

Actavis completes $70.5bn Allergan acquisition

Actavis completes $70.5bn Allergan acquisition Actavis will also be buying into Allergan's lead product Botox, which has over the past five years gained more medical-based licences outside of its cosmetic indications, and is seen

Valeant lead bidder for troubled Dendreon

Valeant lead bidder for troubled Dendreon Valeant's main interest in 2014 was Botox manufacturer Allergan.

Actavis looks to PepsiCo for CFO

Actavis looks to PepsiCo for CFO She now moves to a role in healthcare at Actavis, which is in the middle of increasing its business with the purchase of Allergan, the makers of Botox and several eyecare

Actavis to buy Allergan for $66bn

Actavis to buy Allergan for $66bn Ends Valeant’s pursuit of Botox maker. Allergan has finally put an end to repeated takeover bids from Valeant Pharmaceuticals by accepting a $66bn offer from rival pharma company Actavis. ... Allergan, most well-known as the marketer of Botox for both

[ Previous 5 results ] 5 6 7 8 9 10 11 12 13 14 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Six Degrees Medical Consulting

For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...

Latest intelligence

The search for treatments for Parkinson’s disease
The research requires resilience but pharma is urged to ‘keep innovating, keep trying’...
Margot Hannah, OPEN Health - A personal perspective of LGBT+ and diversity.
Ditch the Label – it’s just me....
The impact of COVID-19 on clinical trials
As all industry sectors work to assess both the impact and the optimal path forward, the effects are expected to be diverse and long-lasting...

Infographics